AstraZeneca shares tumbled 7% after reports of possible talks with Bristol Myers Squibb. This was reported by Qazaqyia.kz citing Reuters.
The market reaction was triggered by the spread of information about a potential deal between the pharmaceutical giants. Investors immediately responded to the news, lowering the value of AstraZeneca's securities.
According to Reuters, this decline significantly impacted the company's market capitalization. However, given that the talks have not been officially confirmed, this market reaction may be temporary.
Information about possible talks with Bristol Myers Squibb has not yet been officially confirmed. The companies have not made official statements on the matter.
Analysts suggest that if the deal goes through, it could lead to significant changes in the pharmaceutical market. However, at present, this is only speculation.
The drop in AstraZeneca shares may be due to uncertainty about the company's future strategy. Investors are trying to assess the terms and consequences of a potential deal.
After Reuters published this news, similar reactions may be observed in global markets. The actions of one of the major players in the pharmaceutical sector could also affect other companies.
Currently, given that the talks between AstraZeneca and Bristol Myers Squibb have not been officially confirmed, the market situation remains unstable. Investors are awaiting new information.